Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4Thoracic 2Gastrointestinal 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Lymphoid 1

Conditions

Neoplasm Metastasis 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Cisplatin 70Paclitaxel 68pembrolizumab 65Carboplatin 61Irinotecan 59Injections 53Gemcitabine 53Docetaxel 49Fluorouracil 35Cyclophosphamide 35Pemetrexed 34Oxaliplatin 31Capecitabine 30Bevacizumab 29Leucovorin 27atezolizumab 23Nivolumab 23tislelizumab 19Etoposide 18Cetuximab 17durvalumab 16Temozolomide 16Bortezomib 16alvocidib 15Topotecan 15olaparib 14Sorafenib 14Rifampin 14Itraconazole 14Erlotinib Hydrochloride 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × LY3023414 × Other solid neoplasm × Clear all
NCT01655225 2022-04-08

A Study of LY3023414 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
156 enrolled
BreastLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lymphoma, Lymphoma, Non-Hodgkin, Mesothelioma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡